The Latest Breaking News from IDEXX

Going under the radar, shares of this vet tech company have been winners this year.

Pet healthcare is witnessing a surge in demand as more households prioritize their pets’ well-being, driving companies in this sector to outperform expectations. This trend is reflected in IDEXX Laboratories Inc.‘s (NASDAQ:IDXX) recent financial results, showcasing significant growth and revised earnings guidance.

IDEXX Laboratories has significantly outperformed the broader market in 2025 and analysts remain bullish on the stock’s prospects.

Idexx Laboratories handily beat Wall Street's fourth-quarter expectations Monday, and Idexx stock gapped up to a four-month high.

IDEXX Laboratories has continued to underperform the S&P 500 over the past year, yet analysts remain moderately bullish on the stock’s prospects.

5 analysts have shared their evaluations of IDEXX Laboratories (NASDAQ:IDXX) during the recent three months, expressing a mix of bullish and bearish perspectives.

IDEXX Laboratories underperformed the broader healthcare sector, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

Smith's popular fund has again underperformed the benchmark, prompting him to defend his Nvidia stance once more.

With an aging population worldwide, the rising prevalence of chronic diseases, and numerous technological advancements, the medical device sector stands primed for considerable growth and expansion. The industry tailwinds should benefit medical device stocks T2 Biosystems (TTOO) and IDEXX Laboratories (IDXX). However, which stock is poised for better gains this…